233 related articles for article (PubMed ID: 20332225)
1. A role for HPV16 E5 in cervical carcinogenesis.
Maufort JP; Shai A; Pitot HC; Lambert PF
Cancer Res; 2010 Apr; 70(7):2924-31. PubMed ID: 20332225
[TBL] [Abstract][Full Text] [Related]
2. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.
Shai A; Brake T; Somoza C; Lambert PF
Cancer Res; 2007 Feb; 67(4):1626-35. PubMed ID: 17308103
[TBL] [Abstract][Full Text] [Related]
3. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells.
Boulenouar S; Weyn C; Van Noppen M; Moussa Ali M; Favre M; Delvenne PO; Bex F; Noël A; Englert Y; Fontaine V
Carcinogenesis; 2010 Mar; 31(3):473-80. PubMed ID: 19917629
[TBL] [Abstract][Full Text] [Related]
4. Loss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-Deficient Mice.
Park S; Park JW; Pitot HC; Lambert PF
mBio; 2016 May; 7(3):. PubMed ID: 27190216
[TBL] [Abstract][Full Text] [Related]
5. The E6/E7 oncogenes of human papilloma virus and estradiol regulate hedgehog signaling activity in a murine model of cervical cancer.
Rojo-León V; García C; Valencia C; Méndez MA; Wood C; Covarrubias L
Exp Cell Res; 2019 Aug; 381(2):311-322. PubMed ID: 31125556
[TBL] [Abstract][Full Text] [Related]
6. HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Peta E; Sinigaglia A; Masi G; Di Camillo B; Grassi A; Trevisan M; Messa L; Loregian A; Manfrin E; Brunelli M; Martignoni G; Palù G; Barzon L
Oncogene; 2018 Mar; 37(12):1654-1668. PubMed ID: 29335520
[TBL] [Abstract][Full Text] [Related]
7. Neoplastic change of squamo-columnar junction in uterine cervix and vaginal epithelium by exogenous estrogen in hpv-18 URR E6/E7 transgenic mice.
Park JS; Rhyu JW; Kim CJ; Kim HS; Lee SY; Kwon YI; Namkoong SE; Sin HS; Um SJ
Gynecol Oncol; 2003 Jun; 89(3):360-8. PubMed ID: 12798696
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer.
Diaz-Chavez J; Hernandez-Pando R; Lambert PF; Gariglio P
Mol Cancer; 2008 Jan; 7():3. PubMed ID: 18184435
[TBL] [Abstract][Full Text] [Related]
9. A mouse model for human anal cancer.
Stelzer MK; Pitot HC; Liem A; Schweizer J; Mahoney C; Lambert PF
Cancer Prev Res (Phila); 2010 Dec; 3(12):1534-41. PubMed ID: 20947489
[TBL] [Abstract][Full Text] [Related]
10. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis.
Balsitis S; Dick F; Dyson N; Lambert PF
Cancer Res; 2006 Oct; 66(19):9393-400. PubMed ID: 17018593
[TBL] [Abstract][Full Text] [Related]
11. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
12. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 16 E6 and E7 gene variations associated with cervical cancer in a Han Chinese population.
Zhou Z; Yang H; Yang L; Yao Y; Dai S; Shi L; Li C; Yang L; Yan Z; Yao Y
Infect Genet Evol; 2019 Sep; 73():13-20. PubMed ID: 30981880
[TBL] [Abstract][Full Text] [Related]
14. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.
Maufort JP; Williams SM; Pitot HC; Lambert PF
Cancer Res; 2007 Jul; 67(13):6106-12. PubMed ID: 17616666
[TBL] [Abstract][Full Text] [Related]
16. HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7.
Liao S; Deng D; Hu X; Wang W; Li L; Li W; Zhou J; Xu G; Meng L; Wang S; Ma D
Int J Mol Med; 2013 Jan; 31(1):120-8. PubMed ID: 23128250
[TBL] [Abstract][Full Text] [Related]
17. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.
Jabbar SF; Abrams L; Glick A; Lambert PF
Cancer Res; 2009 May; 69(10):4407-14. PubMed ID: 19435895
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis of immune characteristics in tumors with alternative carcinogenesis pathways induced by human papillomaviruses.
Smahel M; Nunvar J
Virol J; 2023 Dec; 20(1):287. PubMed ID: 38049810
[TBL] [Abstract][Full Text] [Related]
19. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer.
Chung SH; Wiedmeyer K; Shai A; Korach KS; Lambert PF
Cancer Res; 2008 Dec; 68(23):9928-34. PubMed ID: 19047174
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen.
Spurgeon ME; den Boon JA; Horswill M; Barthakur S; Forouzan O; Rader JS; Beebe DJ; Roopra A; Ahlquist P; Lambert PF
Proc Natl Acad Sci U S A; 2017 Oct; 114(43):E9076-E9085. PubMed ID: 29073104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
